

33

12

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/00</p>	<p>A2</p>	<p>(11) International Publication Number: WO 99/33450 (43) International Publication Date: 8 July 1999 (08.07.99)</p>
<p>(21) International Application Number: PCT/EP98/08249 (22) International Filing Date: 16 December 1998 (16.12.98) (30) Priority Data: 9727131.6 24 December 1997 (24.12.97) GB (71) Applicant (for all designated States except US): KNOLL AKTIENGESELLSCHAFT [DE/DE]; D-67061 Ludwigshafen (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): HEAL, David, John [GB/GB]; R3 Pennyfoot Street, Nottingham NG1 1GF (GB). JACKSON, Helen, Christine [GB/GB]; R3 Pennyfoot Street, Nottingham NG1 1GF (GB). (74) Agents: MILLER, Thomas, Kerr et al.; BASF Aktiengesellschaft, D-67056 Ludwigshafen (DE).</p>		<p>(81) Designated States: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published Without international search report and to be republished upon receipt of that report.</p>

(54) Title: THERAPEUTIC AGENTS



(I)



(II)

(57) Abstract

A method for the treatment of obesity in a human in need of such treatment which comprises administration to the human of therapeutically effective amount of a compound of formula (I) including enantiomers and pharmaceutically acceptable salts thereof, in which R₁ and R₂ are independently H or methyl, and a therapeutically effective amount of a compound of formula (II) wherein the compound of formula (I) and the compound of formula (II) are administered simultaneously, separately or sequentially.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Therapeutic Agents

This invention relates to a method for treating obesity and to products and pharmaceutical compositions suitable for use in such a method. More particularly,
5 the invention relates to a method for the treatment of obesity by the administration of sibutramine or a salt or a metabolite thereof and orlistat and to products and compositions containing such compounds.

Sibutramine hydrochloride monohydrate and orlistat are both currently being
10 developed for use in the treatment of obesity. The two compounds, however, achieve weight loss through entirely different mechanisms.

Sibutramine is a 5-hydroxytryptamine and noradrenaline reuptake inhibitor *in vivo* (Buckett, W.R., Thomas, P.C. & Luscombe, G.P. (1988). Prog. Neuro-
15 Psychopharmacol. Biol. Psychiat. 12, 575-584 and Luscombe, G.P., Hopcroft, R.H., Thomas, P.C. & Buckett, W.R. (1989). Neuropharmacology, 28, 129-134.) Studies have shown that it reduces body weight by a dual mode of action; it decreases food intake by enhancing satiety (Fantino, M. & Souquet, A.-M. (1995). Int. J. Obesity, 19, 145; Halford, J.C.G., Heal, D.J. & Blundell, J.E. (1995). Brit. J. Pharmacol. 114,
20 387P; and Stricker-Krongrad, A., Souquet, A.-M. & Burlet, C. (1995). Int. J. Obesity, 19, 145.), and it increases energy expenditure by stimulating thermogenesis (Connoley, I.P., Heal, D.J. & Stock, M.J. (1995). Brit. J. Pharmacol. 114, 388P; and Connoley, I.P., Frost, I., Heal, D.J. & Stock, M.J. (1996). Brit. J. Pharmacol. 117, 170P).


25

Orlistat inhibits lipase enzymes which are responsible for breaking down ingested fat (Borgstrom, B. (1988). Biochem. Biophys. Acta. 962 (3), 308-316); as a consequence of this, unabsorbed fat is egested in the faeces.


30

It has been reported that orlistat should not be combined with appetite suppressants (The New York Times May 15 1997) . Surprisingly, it has now been found that co-administration of sibutramine hydrochloride monohydrate and orlistat results in beneficial effects with respect to weight-loss.

Accordingly, the present invention provides a method for the treatment of obesity in a human in need of such treatment which comprises administration to the human of a therapeutically effective amount of a compound of formula I



- 5 including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl, and a therapeutically effective amount of a compound of formula II



- 10 wherein the compound of formula I and the compound of formula II are administered simultaneously, separately or sequentially.

The present invention may provide the following advantages. Firstly, the maximum weight loss achieved is greater than that achieved by the sole administration of either a compound of formula I or compound II. Secondly, a synergistic weight loss is achieved in which the weight loss obtained by the administration of a compound of formula I and the compound of formula II to a first test group is greater than the total weight loss achieved by administration of the compound of formula I to a second test group and the weight loss achieved by administration of compound II to a third test group. Thirdly, when weight loss has reached a plateau after administration of either a compound of formula I or the compound II, a further weight loss is achieved by administering the other compound. Fourthly, lower doses of the compound of formula I and the compound of formula II may be used in the present invention thus reducing the side-effects associated with administration of a higher dose of each compound.

A preferred compound of formula I is N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine or a salt thereof, for example the hydrochloride salt, known as sibutramine hydrochloride. A preferred form of this hydrochloride is its monohydrate, known as sibutramine hydrochloride monohydrate.

5

The preparation and use of compounds of formula I, such as N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine and salts thereof, in the treatment of depression is described in British Patent Specification 2098602. The use of compounds of formula I such as N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine and salts thereof in the treatment of Parkinson's disease is described in published PCT application WO 88/06444. The use of N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine and salts thereof in the treatment of cerebral function disorders is described in US Patent 4939175. The use of N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride in the treatment of obesity is described in European Patent Number 397831. A particularly preferred form of this compound is N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride monohydrate (sibutramine hydrochloride monohydrate) which is described in European Patent Number 230742. The use of N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine and salts thereof for improving the glucose tolerance of humans having Impaired Glucose Tolerance or Non-Insulin Dependent Diabetes Mellitus is described in published PCT application WO95/20949.

The compound of formula II has the chemical name (2S, 3S, 5S)-5-[(S)-2-formamido-4-methylvaleryloxy]-2-hexyl-3-hydroxyhexadecanoic acid lactone. It is also known as "N-formyl-L-leucine, ester with (3S, 4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]-2-oxetanone", (-)-tetrahydrolipstatin, tetrahydrolipstatin, and orlistat.

The extraction and use of orlistat in the control or prevention of obesity and hyperlipaemia is described in US Patent 4598089 (Hoffmann-La Roche Inc.). A process for the preparation of orlistat is described in US Patent 4983746 (Hoffmann-La Roche Inc.). A composition comprising orlistat and acarbose is described in EP638317 (Hoffmann-La Roche AGF).

It will be appreciated by those skilled in the art that compounds of formula I contain a chiral centre. When a compound of formula I contains a single chiral centre it may exist in two enantiomeric forms. The present invention includes the use of the individual enantiomers and mixtures of the enantiomers. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallisation; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallisation, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesised by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation. Enantiomers of secondary and tertiary amines of formula I can also be prepared by preparing the primary amine racemate, resolving this mixture into its individual enantiomers and then converting the relevant optically pure primary amine enantiomer into the desired secondary or tertiary amine product.

Preferred compounds of formula I are N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine, N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine, and N-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine including racemates, individual enantiomers and mixtures thereof, and pharmaceutically acceptable salts thereof. Specific enantiomers of formula I are (+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine, (-)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine, (R)-(+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine, (S)-(-)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine, (R)-(+)-1-[1-(4-chloro-

phenyl)cyclobutyl]-3-methylbutylamine and (S)-(-)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine.

5 In the method of the present invention a compound of formula I and the compound of formula II may be administered concomitantly or concurrently, for example in the form of separate dosage units to be used simultaneously, separately or sequentially.

10 In another aspect the present invention provides a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II for simultaneous, separate or sequential use for the treatment of obesity.

15 In yet another aspect the present invention provides a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of obesity.

20 In a further aspect the present invention provides a product containing a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of obesity.

25 In yet another aspect the present invention provides the use of a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl in the manufacture of a medicament for the treatment of obesity in a patient who is also receiving treatment with orlistat.


30 In a further aspect, the present invention provides a method of treating obesity comprising the administration of an adjunctive therapy comprising a therapeutically effective amount of a compound of formula I and orlistat to a patient in need thereof.

The invention also provides the use of the above combination of drugs in the manufacture of a medicament for the treatment of obesity. Additionally, it provides the combination for use in the treatment of obesity.


5 The amount of each compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage of the compound of formula I to be administered will be in the range 0.1 to 50 mg preferably
 10 1 to 30 mg per day given in one or more doses and more preferably 10 mg, 15 mg, 20 mg, 25 mg or 30 mg per day and most preferably 20 mg. The dosage of orlistat to be administered will be in the range of 50 to 1440 mg given in one or more doses, preferably three times daily, more preferably in the range of 120 to 720 mg and most preferably in the range of 120 to 360 mg. The compound of formula I, preferably
 15 sibutramine hydrochloride monohydrate, may be administered in any of the known pharmaceutical dosage forms. Orlistat is preferably administered orally.

In a preferred aspect of the present invention sibutramine hydrochloride monohydrate is administered once daily, preferably first thing in the morning, and
 20 orlistat is administered three times daily either with or before meals. Preferably the dose of sibutramine hydrochloride monohydrate is 20 mg or 30 mg administered once daily and the dose of orlistat is 120 mg administered three times daily either with or before meals. Most preferably the dose of sibutramine hydrochloride monohydrate is given prior to the first dose of orlistat, preferably in the range of 30
 25 minutes to 3 hours, for example 30 minutes, 1 hour, 1.5 hours, 2 hours, 2.5 hours or 3 hours, before the first dose orlistat.

In another aspect of to the present invention there is provided a pharmaceutical composition comprising a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl, and the compound of formula II



In conjunction with a pharmaceutically acceptable diluent or carrier.

5 Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for example tablets, capsules, granules, syrups and aqueous or oil suspensions. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art. Tablets may be prepared from a mixture of the active compounds with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders, for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods. The tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate. The tablets may be formulated in a manner known to those skilled in the art so as to give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner. The contents of the capsule may be formulated using known methods so as to give sustained release of the active compound. The tablets and capsules may conveniently each contain 1 to 50 mg of the compound of formula I and 1 to 360 mg of orlistat.

Other dosage forms for oral administration include, for example, aqueous suspensions containing the active compounds in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy-methylcellulose, and oily suspensions containing the active compounds in a suitable vegetable oil, for example arachis oil. The active compounds may be formulated into granules with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion. The granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.

The compounds of formula I and orlistat may be formulated into a composition which the patient retains in his mouth so that the active compounds are administered through the mucosa of the mouth.

Dosage forms of the compounds of formula I suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.

Dosage forms of the compounds of formula I suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.

Dosage forms of the compounds of formula I for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. A suitable transdermal composition may be prepared by mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol. Alternatively the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base. The amount of each active compound contained in a topical formulation should be such that a therapeutically effective amount of each compound is delivered during the period of time for which the topical formulation is intended to be on the skin.

The compounds of formula I may be formulated into a composition which is dispersed as an aerosol into the patients oral or nasal cavity. Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile
5 propellant.

The compound of formula I may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources include implanted
10 reservoirs containing the compounds to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the compounds to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or
15 (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compounds to be infused. The support may be a single body containing all the compounds or a series of several bodies each containing part of the compounds to be delivered. The amount of active compounds present in an internal source should be such that a therapeutically effective amount of each compound is delivered over a long period of time.

20 In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.

25 In the compositions of the present invention the active compounds may, if desired, be associated with other compatible pharmacologically active ingredients. Optionally vitamin supplements may be administered with the compounds of the present invention.

30 Pharmaceutical compositions incorporating both a compound of formula I and orlistat are important embodiments of the present invention. Such pharmaceutical compositions contain a therapeutically effective amount of each of the compounds. Each dosage unit may contain the daily doses of both compounds, or may contain a fraction of the daily dose, such as one-third of the doses. Alternatively, each dosage

unit may contain the entire dose of one of the compounds, and a fraction of the dose of the other compound. In such case, the patient would daily take one of the combination dosage units, and one or more units containing only the other compound.

5

The use of compounds of the present invention in the manufacture of pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes either or both compounds of the invention unless otherwise stated.

10

a) Capsules

In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose are de-aggregated and blended. The mixture is filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound.

b) Tablets

20

Tablets are prepared from the following ingredients.

	<u>Parts by weight</u>
Active compound	10
Lactose	190
Maize starch	22
25 Polyvinylpyrrolidone	10
Magnesium stearate	3

The active compound, the lactose and some of the starch are de-aggregated, blended and the resulting mixture is granulated with a solution of the polyvinylpyrrolidone in ethanol. The dry granulate is blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in a tableting machine to give tablets each containing a unit dose or a part of a unit dose of active compound.

30

Enteric coated tablets

Tablets are prepared by the method described in (b) above. The tablets are enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1:1).

d) Suppositories (Compound of formula I only)

In the preparation of suppositories, 100 parts by weight of active compound is incorporated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of active ingredient.

15 Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Sibutramine hydrochloride monohydrate	20
Orlistat	120
Starch	200
Magnesium stearate	10
Total	350

20 Formulation 2

A tablet is prepared using the ingredients below:

	Quantity (mg/tablet)
Sibutramine hydrochloride monohydrate	10
Orlistat	120
Microcrystalline Cellulose	400
Silica	10

	Quantity (mg/tablet)
Stearic acid	5
Total	545

The components are blended and compressed to form tablets each weighing 545 mg.

5

The advantages of the present invention may be demonstrated by one or more of the following studies

Study 1

10

Groups of normal adult male Sprague-Dawley CD rats (n = 8-12) receive the following treatments

- a) Group 1; daily dosing with sibutramine hydrochloride monohydrate (1, 3 or 10 mg/kg po) plus orlistat vehicle po.
- 15 b) Group 2; bidaily dosing of orlistat po (for example 10, 20, 30 or 40 mg/kg po preferably 10 or 20 mg/kg) plus sibutramine vehicle po.
- c) Group 3; combined po treatment with doses of sibutramine hydrochloride monohydrate and orlistat.
- d) Group 4; control, dosed po with sibutramine and orlistat vehicles.

20

The rats are allowed free access to high-fat diet. Food intake, water intake and body-weight are measured daily and the duration of treatment is 15, 21 or 28 days. A statistical comparison between the body weights of the animals in each group provides results demonstrating the advantage of the present invention.

25

Study 2

Groups of obese female Zucker rats (n = 8-12) maintained on a high-fat diet receive the following treatments

- 30 a) Group 1; daily po dosing with sibutramine hydrochloride monohydrate for 14 days at a dose which significantly reduces body weight compared to vehicle-


treated controls (1, 3 or 10 mg/kg po). Daily treatment for the next 14 days is with an identical dose of sibutramine hydrochloride monohydrate po plus a dose of orlistat (for example 10, 20, 30 or 40 mg/kg po preferably 10 or 20 mg/kg).

- 5 b) Group 2; daily dosing with sibutramine hydrochloride monohydrate po for 14 days. Daily treatment for the next 14 days with sibutramine po and orlistat vehicle po.
- c) Group 3; daily dosing with sibutramine hydrochloride monohydrate vehicle po for 14 days followed by combined treatment with sibutramine hydrochloride monohydrate vehicle po and orlistat vehicle po for the following 14 days.
- 10


A statistical comparison between the body weights of animals in each group provides results demonstrating the advantage of the present invention.

Claims

- 1) A method for the treatment of obesity in a human in need of such treatment
 5 which comprises administration to the human of a therapeutically effective amount of a compound of formula I



- including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl, and a therapeutically effective amount of a
 10 compound of formula II




wherein the compound of formula I and the compound of formula II are administered simultaneously, separately or sequentially.


- 15 2) A method according to claim 1 in which the compound of formula I is N-(1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl)-N,N-dimethylamine or a salt thereof.
- 3) A method according to claim 2 wherein the compound of formula I is administered 30 minutes to 3 hours prior to the administration of the compound of
 20 formula II.
- 4) A compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the

compound of formula II for simultaneous, separate or sequential use for the treatment of obesity.

- 5) A compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of obesity.
- 6) A product containing a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl and the compound of formula II as a combined preparation for simultaneous, separate or sequential use for the treatment of obesity.
- 7) The use of a compound of formula I including enantiomers and pharmaceutically acceptable salts thereof, in which R_1 and R_2 are independently H or methyl in the manufacture of a medicament for the treatment of obesity in a patient who is also receiving treatment with orlistat.
- 8) A pharmaceutical composition comprising a compound of formula I



including enantiomers and pharmaceutically acceptable salts thereof, in which R₁ and R₂ are independently H or methyl, and the compound of formula II



in conjunction with a pharmaceutically acceptable diluent or carrier.


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/365 // (A61K 31/365, 31:135)	A3	(11) International Publication Number: WO 99/33450 (43) International Publication Date: 8 July 1999 (08.07.99)
(21) International Application Number: PCT/EP98/08249 (22) International Filing Date: 16 December 1998 (16.12.98) (30) Priority Data: 9727131.6 24 December 1997 (24.12.97) GB (71) Applicant (for all designated States except US): KNOLL AKTIENGESELLSCHAFT [DE/DE]; D-67061 Ludwigshafen (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): HEAL, David, John [GB/GB]; R3 Pennyfoot Street, Nottingham NG1 1GF (GB). JACKSON, Helen, Christine [GB/GB]; R3 Pennyfoot Street, Nottingham NG1 1GF (GB). (74) Agents: MILLER, Thomas, Kerr et al.; BASF Aktiengesellschaft, D-67056 Ludwigshafen (DE).	(81) Designated States: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> (88) Date of publication of the international search report: 2 September 1999 (02.09.99)	

(54) Title: PHARMACEUTICAL COMPOSITION CONTAINING SIBUTRAMINE AND ORLISTAT



(I)



(II)

(57) Abstract

A method for the treatment of obesity in a human in need of such treatment which comprises administration to the human of therapeutically effective amount of a compound of formula (I) including enantiomers and pharmaceutically acceptable salts thereof, in which R₁ and R₂ are independently H or methyl, and a therapeutically effective amount of a compound of formula (II) wherein the compound of formula (I) and the compound of formula (II) are administered simultaneously, separately or sequentially.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Inte. .onal Application No

PCT/EP 98/08249

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/365 //(A61K31/365,31:135)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BUTTLE L.A.: "Anti-obesity drugs: On target for huge market sales" EXPERT OPINION ON INVESTIGATIONAL DRUGS(EXPERT OPIN. INVEST. DRUGS), 5/12 (1583-1587), XP002105328 United Kingdom see page 1584, column 2, paragraph 5 - page 1586, column 2, paragraph 1 see page 1587, column 1, paragraph 3 ---	1,2,4-8
A	WILDING, J.: "OBESITY TREATMENT" BRITISH MEDICAL JOURNAL (ENGLAND), V315, (OCT 18), P997-1000, 1997, XP002105329 see page 999, column 2, paragraph 4 - page 1000, column 1, paragraph 2 --- -/--	1-8

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 June 1999

Date of mailing of the international search report

21/06/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/08249

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FINER N.: "Present and future pharmacological approaches" BRITISH MEDICAL BULLETIN(BR. MED. BULL.), 53/2 (409-432), XP002105330 United Kingdom see page 422, paragraph 2 - page 423, paragraph 1</p> <p>-----</p>	1-8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/08249

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-3
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.